Proton Pump

Proton Pump製品

All (22)
Proton Pump阻害剤 (22)
新製品

製品コード	製品名称	製品説明	文献中Selleckの製品使用例
S1413	Bafilomycin A1 (Baf-A1)	バフィロマイシン A1 (Bafilomycin A1(Baf-A1)) は液胞 H⁺-ATPase 阻害剤で、IC50 は 0.44 nM です。バフィロマイシン A1 は、オートファジー (autophagy) を阻害する一方で、アポトーシス (apoptosis) を誘導することがわかっています。	Nature, 2024, 626(8000):874-880 Nature, 2024, 626(8000):874-880 Cell, 2024, 187(21):6055-6070.e22
S1389	Omeprazole	Omeprazole is a proton pump inhibitor that blocks H(+)-K(+)-ATPase, used to treat dyspepsia, peptic ulcer disease, gastroesophageal reflux disease, laryngopharyngeal reflux, and Zollinger–Ellison syndrome.	J Extracell Vesicles, 2024, 13(4):e12426 J Extracell Vesicles, 2024, 13(4):e12426 J Transl Med, 2024, 22(1):676
S4845	Rabeprazole	Rabeprazole(LY307640) is an oral inhibitor of proton pump and blocks the production of acid by the stomach.	J Extracell Vesicles, 2024, 13(4):e12426 Med Oncol, 2024, 41(8):188 PLoS Genet, 2022, 18(3):e1010128
S5658	Omeprazole Sodium	Omeprazole Sodium is the sodium salt form of omeprazole, which is a proton pump inhibitor and suppresses gastric acid secretion. Omeprazole Sodium is a metabolism-dependent inhibitor (MDI) of CYP2C19.	Theranostics, 2021, 11(5):2364-2380 Theranostics, 2021, 11(5):2364-2380 J Virol, 2021, JVI.00190-21
S2105	Pantoprazole	Pantoprazole (SKF96022, BY-1023) is a proton pump inhibitor drug that inhibits gastric acid secretion. It works on gastric parietal cells to irreversibly inhibit (H+/K+)-ATPase function and suppress the production of gastric acid.	Med Oncol, 2024, 41(8):188 Int J Mol Sci, 2022, 23-158572 Eur J Drug Metab Pharmacokinet, 2022, 10.1007/s13318-022-00780-x
S1354	Lansoprazole	Lansoprazole (A-65006, AG-1749) is a proton-pump inhibitor (PPI) that binds covalently to parietal cell H(+),K(+)-ATPase. Lansoprazole prevents the stomach from producing gastric acid.	Front Cell Dev Biol, 2021, 9:655559 J Virol, 2021, JVI.00190-21 Front Microbiol, 2019, 10:2790
S4075	Zinc Pyrithione	Zinc pyrithione (OM-1563) is an antifungal and antibacterial agent disrupting membrane transport by blocking the proton pump.	Cell Chem Biol, 2021, S2451-9456(21)00213-0 Biol Reprod, 2019, 100(2):468-478 Cell Syst, 2017, 4(6-:600-610
S4099	Dexlansoprazole	Dexlansoprazole (T 168390, TAK 390,(R)-Lansoprazole), the dextrorotatory enantiomer of lansoprazole, is a proton pump inhibitor (PPI) formulated to have dual delayed-release properties. Dexlansoprazole selectively suppresses gastric acid secretion by direct inhibition of the H(+),K(+)-ATPase proton pump in the gastric parietal cell.	J Virol, 2021, JVI.00190-21 Front Microbiol, 2019, 10:2790
S5608	Pantoprazole sodium hydrate	Pantoprazole (BY10232, SKF96022) sodium hydrate (Protonix) is a potent inhibitor of H+/K(+)-ATPase with IC50 of 6.8 μM.	Eur J Drug Metab Pharmacokinet, 2022, 10.1007/s13318-022-00780-x J Virol, 2021, JVI.00190-21
S4538	Pantoprazole sodium	Pantoprazole (SKF96022, BY-1023) is a proton pump inhibitor drug that inhibits gastric acid secretion. It works on gastric parietal cells to irreversibly inhibit (H+/K+)-ATPase function and suppress the production of gastric acid.	Eur J Drug Metab Pharmacokinet, 2022, 10.1007/s13318-022-00780-x J Virol, 2021, JVI.00190-21
S5885	Rabeprazole Related Compound E	Rabeprazole Related Compound E (Rabeprazole thioether) is an active metabolite of rabeprazole, which is a proton pump inhibitor.	Stem Cells Int, 2022, 2022:1396735
S5502	Ilaprazole sodium	Ilaprazole (IY-81149) sodium is the sodium salt form of ilaprazole, which is a proton pump inhibitor. Ilaprazole sodium irreversibly inhibits H(+)/K(+)-ATPase in a dose-dependent manner with IC50 of 6 μM in rabbit parietal cell preparation.	J Virol, 2021, JVI.00190-21
S3666	Ilaprazole	Ilaprazole (IY-81149) is a new proton pump inhibitor (PPI) used in the treatment of dyspepsia, peptic ulcer disease (PUD), gastroesophageal reflux disease (GORD/GERD) and duodenal ulcer. It inhibits H+/K+-ATPase with an IC50 of 6.0 μM.	Med Oncol, 2024, 41(8):188 J Virol, 2021, JVI.00190-21
S4212	Tenatoprazole	Tenatoprazole (TU-199,STU-Na) is a prodrug of the proton pump inhibitor (PPI) class, which inhibits proton transport with IC50 of 3.2 μM. Tenatoprazole labels only the gastric H(+),K(+)-ATPase alpha-subunit, approximately 2.6 nM/mg of tenatoprazole is bound to the H(+),K(+)-ATPase.	J Virol, 2021, JVI.00190-21
S4665	Rabeprazole sodium	Rabeprazole (Aciphex, Dexrabeprazole, Habeprazole) is an antiulcer drug in the class of proton pump inhibitors.	J Virol, 2021, JVI.00190-21
S5058	Revaprazan Hydrochloride	Revaprazan Hydrochloride (YH1885) is a new reversible proton pump inhibitor with long-lasting acid-suppressive effects. Revaprazan Hydrochloride reversibly inhibits H(+)/K(+)-ATPase via binding to the K+-binding site of the pump.	ACS Infect Dis, 2021, 10.1021/acsinfecdis.0c00754
S1743	Esomeprazole magnesium	Esomeprazole Magnesium(NEXIUM) is a proton pump inhibitor to reduce gastric acid secretion through inhibition of H(+)/K(+)-ATPase in gastric parietal cells.
S2222	PF-3716556	PF 3716556 is a potent and selective P-CAB (potassium-competitive acid blocker), with pIC50 of 6.026 and 7.095 for the inhibition of porcine H⁺,K⁺-ATPase activity in ion-leaky and ion-tight assay, respectively, inhibits gastric acid secretion, displays no activity at Na⁺,K⁺-ATPase, used for the treatment of gastroesophageal reflux disease.
E4988^New	Vonoprazan Fumarate	Vonoprazan Fumarate(TAK-438), is a potent, orally active inhibitor of proton pump, specifically a potassium-competitive acid blocker (P-CAB), inhibiting H+,K+-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. It exhibits potent antisecretory activity and can be used in research of acid-related disease.
E4878^New	Lansoprazole sodium	Lansoprazole Sodium, a sodium salt form of Lansoprazole, is an orally active inhibitor of proton pump, preventing the stomach from producing acid. Lansoprazole enhances the expression and transcriptional effectiveness of runt-related transcription factor 2 (Runx2), stimulating osteoprogenitor cell's commitment and differentiation toward their lineage.
S5847	Ethacrynate Sodium	Ethacrynate Sodium (ethacrynic acid sodium) is the sodium salt form of ethacrynic acid, which inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules.
S6438	Ufiprazole	Ufiprazole (Omeprazole sulfide) is an intermediate used in the production of the gastric proton pump inhibitors omeprazole and esomeprazole.
S1413	Bafilomycin A1 (Baf-A1)	バフィロマイシン A1 (Bafilomycin A1(Baf-A1)) は液胞 H⁺-ATPase 阻害剤で、IC50 は 0.44 nM です。バフィロマイシン A1 は、オートファジー (autophagy) を阻害する一方で、アポトーシス (apoptosis) を誘導することがわかっています。	Nature, 2024, 626(8000):874-880 Nature, 2024, 626(8000):874-880 Cell, 2024, 187(21):6055-6070.e22
S1389	Omeprazole	Omeprazole is a proton pump inhibitor that blocks H(+)-K(+)-ATPase, used to treat dyspepsia, peptic ulcer disease, gastroesophageal reflux disease, laryngopharyngeal reflux, and Zollinger–Ellison syndrome.	J Extracell Vesicles, 2024, 13(4):e12426 J Extracell Vesicles, 2024, 13(4):e12426 J Transl Med, 2024, 22(1):676
S4845	Rabeprazole	Rabeprazole(LY307640) is an oral inhibitor of proton pump and blocks the production of acid by the stomach.	J Extracell Vesicles, 2024, 13(4):e12426 Med Oncol, 2024, 41(8):188 PLoS Genet, 2022, 18(3):e1010128
S5658	Omeprazole Sodium	Omeprazole Sodium is the sodium salt form of omeprazole, which is a proton pump inhibitor and suppresses gastric acid secretion. Omeprazole Sodium is a metabolism-dependent inhibitor (MDI) of CYP2C19.	Theranostics, 2021, 11(5):2364-2380 Theranostics, 2021, 11(5):2364-2380 J Virol, 2021, JVI.00190-21
S2105	Pantoprazole	Pantoprazole (SKF96022, BY-1023) is a proton pump inhibitor drug that inhibits gastric acid secretion. It works on gastric parietal cells to irreversibly inhibit (H+/K+)-ATPase function and suppress the production of gastric acid.	Med Oncol, 2024, 41(8):188 Int J Mol Sci, 2022, 23-158572 Eur J Drug Metab Pharmacokinet, 2022, 10.1007/s13318-022-00780-x
S1354	Lansoprazole	Lansoprazole (A-65006, AG-1749) is a proton-pump inhibitor (PPI) that binds covalently to parietal cell H(+),K(+)-ATPase. Lansoprazole prevents the stomach from producing gastric acid.	Front Cell Dev Biol, 2021, 9:655559 J Virol, 2021, JVI.00190-21 Front Microbiol, 2019, 10:2790
S4075	Zinc Pyrithione	Zinc pyrithione (OM-1563) is an antifungal and antibacterial agent disrupting membrane transport by blocking the proton pump.	Cell Chem Biol, 2021, S2451-9456(21)00213-0 Biol Reprod, 2019, 100(2):468-478 Cell Syst, 2017, 4(6-:600-610
S4099	Dexlansoprazole	Dexlansoprazole (T 168390, TAK 390,(R)-Lansoprazole), the dextrorotatory enantiomer of lansoprazole, is a proton pump inhibitor (PPI) formulated to have dual delayed-release properties. Dexlansoprazole selectively suppresses gastric acid secretion by direct inhibition of the H(+),K(+)-ATPase proton pump in the gastric parietal cell.	J Virol, 2021, JVI.00190-21 Front Microbiol, 2019, 10:2790
S5608	Pantoprazole sodium hydrate	Pantoprazole (BY10232, SKF96022) sodium hydrate (Protonix) is a potent inhibitor of H+/K(+)-ATPase with IC50 of 6.8 μM.	Eur J Drug Metab Pharmacokinet, 2022, 10.1007/s13318-022-00780-x J Virol, 2021, JVI.00190-21
S4538	Pantoprazole sodium	Pantoprazole (SKF96022, BY-1023) is a proton pump inhibitor drug that inhibits gastric acid secretion. It works on gastric parietal cells to irreversibly inhibit (H+/K+)-ATPase function and suppress the production of gastric acid.	Eur J Drug Metab Pharmacokinet, 2022, 10.1007/s13318-022-00780-x J Virol, 2021, JVI.00190-21
S5885	Rabeprazole Related Compound E	Rabeprazole Related Compound E (Rabeprazole thioether) is an active metabolite of rabeprazole, which is a proton pump inhibitor.	Stem Cells Int, 2022, 2022:1396735
S5502	Ilaprazole sodium	Ilaprazole (IY-81149) sodium is the sodium salt form of ilaprazole, which is a proton pump inhibitor. Ilaprazole sodium irreversibly inhibits H(+)/K(+)-ATPase in a dose-dependent manner with IC50 of 6 μM in rabbit parietal cell preparation.	J Virol, 2021, JVI.00190-21
S3666	Ilaprazole	Ilaprazole (IY-81149) is a new proton pump inhibitor (PPI) used in the treatment of dyspepsia, peptic ulcer disease (PUD), gastroesophageal reflux disease (GORD/GERD) and duodenal ulcer. It inhibits H+/K+-ATPase with an IC50 of 6.0 μM.	Med Oncol, 2024, 41(8):188 J Virol, 2021, JVI.00190-21
S4212	Tenatoprazole	Tenatoprazole (TU-199,STU-Na) is a prodrug of the proton pump inhibitor (PPI) class, which inhibits proton transport with IC50 of 3.2 μM. Tenatoprazole labels only the gastric H(+),K(+)-ATPase alpha-subunit, approximately 2.6 nM/mg of tenatoprazole is bound to the H(+),K(+)-ATPase.	J Virol, 2021, JVI.00190-21
S4665	Rabeprazole sodium	Rabeprazole (Aciphex, Dexrabeprazole, Habeprazole) is an antiulcer drug in the class of proton pump inhibitors.	J Virol, 2021, JVI.00190-21
S5058	Revaprazan Hydrochloride	Revaprazan Hydrochloride (YH1885) is a new reversible proton pump inhibitor with long-lasting acid-suppressive effects. Revaprazan Hydrochloride reversibly inhibits H(+)/K(+)-ATPase via binding to the K+-binding site of the pump.	ACS Infect Dis, 2021, 10.1021/acsinfecdis.0c00754
S1743	Esomeprazole magnesium	Esomeprazole Magnesium(NEXIUM) is a proton pump inhibitor to reduce gastric acid secretion through inhibition of H(+)/K(+)-ATPase in gastric parietal cells.
S2222	PF-3716556	PF 3716556 is a potent and selective P-CAB (potassium-competitive acid blocker), with pIC50 of 6.026 and 7.095 for the inhibition of porcine H⁺,K⁺-ATPase activity in ion-leaky and ion-tight assay, respectively, inhibits gastric acid secretion, displays no activity at Na⁺,K⁺-ATPase, used for the treatment of gastroesophageal reflux disease.
E4988^New	Vonoprazan Fumarate	Vonoprazan Fumarate(TAK-438), is a potent, orally active inhibitor of proton pump, specifically a potassium-competitive acid blocker (P-CAB), inhibiting H+,K+-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. It exhibits potent antisecretory activity and can be used in research of acid-related disease.
E4878^New	Lansoprazole sodium	Lansoprazole Sodium, a sodium salt form of Lansoprazole, is an orally active inhibitor of proton pump, preventing the stomach from producing acid. Lansoprazole enhances the expression and transcriptional effectiveness of runt-related transcription factor 2 (Runx2), stimulating osteoprogenitor cell's commitment and differentiation toward their lineage.
S5847	Ethacrynate Sodium	Ethacrynate Sodium (ethacrynic acid sodium) is the sodium salt form of ethacrynic acid, which inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules.
S6438	Ufiprazole	Ufiprazole (Omeprazole sulfide) is an intermediate used in the production of the gastric proton pump inhibitors omeprazole and esomeprazole.
E4988^New	Vonoprazan Fumarate	Vonoprazan Fumarate(TAK-438), is a potent, orally active inhibitor of proton pump, specifically a potassium-competitive acid blocker (P-CAB), inhibiting H+,K+-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. It exhibits potent antisecretory activity and can be used in research of acid-related disease.
E4878^New	Lansoprazole sodium	Lansoprazole Sodium, a sodium salt form of Lansoprazole, is an orally active inhibitor of proton pump, preventing the stomach from producing acid. Lansoprazole enhances the expression and transcriptional effectiveness of runt-related transcription factor 2 (Runx2), stimulating osteoprogenitor cell's commitment and differentiation toward their lineage.

Proton Pump阻害剤の選択性比較

Proton Pumpシグナル伝達経路